胶质肉瘤DNA拷贝数/SNP芯片分析揭示独特分子通路与基因组改变
本研究对18例胶质肉瘤行OncoScan®拷贝数微阵列分析并用MetaCore™富集通路,发现拷贝数丢失最常见(占57%),9号和10号染色体丢失最多且多与CDKN2A/B丢失相关,增益多位于7号染色体,扩增少见(4.6%)尤其EGFR,提示这些改变可能是胶质肉瘤发生的关键驱动。
要点
- 拷贝数丢失占全部拷贝数改变的57%,远多于扩增与LOH事件(均P<0.001)。
- 9号和10号染色体丢失最多,很大部分对应CDKN2A/B丢失。
- 增益占26.2%且多在7号染色体,扩增仅4.6%,EGFR扩增少见。
核心结论
- 胶质肉瘤以拷贝数丢失为主,9/10号染色体丢失及CDKN2A/B丢失常见,相关通路或为其发生关键驱动。
研究设计与样本
- 对18例胶质肉瘤行OncoScan®细胞基因组DNA拷贝数微阵列分析,并用MetaCore™富集检测相关分子通路。
主要发现
- 拷贝数丢失占全部拷贝数改变的57%,显著多于扩增与LOH事件(均P<0.001)。
- 扩增少见(4.6%),尤其EGFR;增益占26.2%,多数位于7号染色体。
- 9号和10号染色体丢失最多,很大部分与CDKN2A/B丢失相关。
关键数值与推荐
- 拷贝数增益富集通路包括HOXA、Rho家族GTPases和EGFR。
- 拷贝数丢失富集通路包括WNT、NF-kß和CDKN2A。
- LOH富集通路包括WNT和p53。
临床怎么用
- 可将检测到的拷贝数改变与通路作为胶质肉瘤靶向肿瘤学分析的起点,探索潜在治疗靶点。
局限性
- 原文未报告具体样本特征、随访与生存分析等局限信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Gliosarcoma is a histologic variant of glioblastoma (GBM), and like GBM carries a poor prognosis. Median survival is less than one (1) year with less than 5% of patients alive after 5 years. Although there is no cure, standard treatment includes surgery, radiation and chemotherapy. While very similar to GBM, gliosarcoma exhibits several distinct differences, morphologically and molecularly. Therefore, we report a comprehensive analysis of DNA copy number changes in gliosarcoma using a cytogenomic DNA copy number (CN) microarray (OncoScan®). METHODS: Cytogenomic DNA copy number microarray (OncoScan®) was performed on 18 cases of gliosarcoma. MetaCore™ enrichment was applied to the array results to detect associated molecular pathways. RESULTS: The most frequent alteration was copy number loss, comprising 57% of total copy number changes. The number of losses far exceeded the number of amplifications (***, < 0.001) and loss of heterozygosity events (***, < 0.001). Amplifications were infrequent (4.6%), particularly for EGFR. Chromosomes 9 and 10 had the highest number of losses; a large portion of which correlated to CDKN2A/B loss. Copy number gains were the second most common alteration (26.2%), with the majority occurring on chromosome 7. MetaCore™ enrichment detected notable pathways for copy number gains including: HOXA, Rho family of GTPases, and EGFR; copy number loss including: WNT, NF-kß, and CDKN2A; and copy number loss of heterozygosity including: WNT and p53. CONCLUSIONS: The pathways and copy number alterations detected in this study may represent key drivers in gliosarcoma oncogenesis and may provide a starting point toward targeted oncologic analysis with therapeutic potential.
引用
- Lowder L, Hauenstein J, Woods A, et al. Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. J Neurooncol. 2019. PMID: 31073965. doi:10.1007/s11060-019-03184-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。